+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Monotherapy versus Combination Therapy against Nonbacteremic Carbapenem-resistant Gram-negative Infections: A Retrospective Observational Study

Monotherapy versus Combination Therapy against Nonbacteremic Carbapenem-resistant Gram-negative Infections: A Retrospective Observational Study

Indian Journal of Critical Care Medicine 21(12): 825-829

Superiority of colistin-carbapenem combination therapy (CCCT) over colistin monotherapy (CMT) against carbapenem-resistant Gram-negative bacterial (CRGNB) infections is not conclusively proven. The aim of the current study was to analyze the effectiveness of both strategies against CRGNB nonbacteremic infections. This was a retrospective observational cohort study. Case record analysis of patients who had CRGNB nonbacteremic infections identified over a period of 4 years (January 2012-December 2015) was done by medical record review at a tertiary care center in India. P < 0.05 was considered as significant. Multivariate analysis was performed using Cox regression. Out of 153 patients (pneumonia 115, urinary tract infection 17, complicated skin and soft-tissue infection 18, intra-abdominal infection 1, and meningitis 2), 92 patients received CCCT and 61 received CMT. Univariate analysis revealed higher Acute Physiology and Chronic Health Evaluation II (APACHE II) score, pneumonia as the diagnosis, and Klebsiella as the causative organism to be the risk factors for higher 28-day mortality (P = 0.036, 0.006, 0.016, respectively). Combination therapy had no significant impact on mortality (odds ratio [OR] = 0.91, 95% confidence interval [CI] = 0.327-2.535, P = 0.857). Multivariate analysis revealed that higher APACHE II score and infection due to Klebsiella were found to be independent risk factors for higher mortality (OR = 3.16 and 4.9, 95% CI = 1.34-7.4 and 2.19-11.2, P = 0.008 and 0.0001, respectively). In our retrospective single-center series of CRGNB nonbacteremic infections, CCCT was not superior to CMT. Multicenter large observational studies or prospective randomized clinical trials are the need of the hour.

(PDF emailed within 0-6 h: $19.90)

Accession: 065331104

Download citation: RISBibTeXText

PMID: 29307962

DOI: 10.4103/ijccm.IJCCM_243_17

Related references

Monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria: A retrospective observational study. Indian Journal of Cancer 53(4): 592-594, 2018

Intravenous Colistin Monotherapy versus Combination Therapy against Carbapenem-Resistant Gram-Negative Bacteria Infections: Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 7(8): -, 2018

Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections. Antimicrobial Agents and ChemoTherapy 60(7): 4013-4022, 2017

Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scandinavian Journal of Infectious Diseases 46(1): 1-8, 2014

Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrobial Agents and ChemoTherapy 41(5): 1127-1133, 1997

Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: Risk factors and outcome. Diagnostic Microbiology and Infectious Disease 87(4): 359-364, 2017

Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clinical Microbiology and Infection 12(12): 1227-1230, 2006

Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Review of Anti-Infective Therapy 11(12): 1333-1353, 2014

Combination therapy for carbapenem-resistant Gram-negative bacteria. Journal of Antimicrobial ChemoTherapy 69(9): 2305-2309, 2015

Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens. Infection & ChemoTherapy 46(3): 149-164, 2014

Combination therapy vs. monotherapy for Gram-negative bloodstream infection: matching by predicted prognosis. International Journal of Antimicrobial Agents: -, 2017

Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study. Biomed Research International 2016: 8395268-8395268, 2017

Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: A commentary. International Journal of Antimicrobial Agents 11(1): 7-12, 1999

Monotherapy versus beta-lactam-aminoglycoside combination therapy for gram-negative bacteremia. Antimicrobial Agents and ChemoTherapy 41(11): 2593-2594, 1997

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. International Journal of Antimicrobial Agents 35(2): 194-199, 2010